Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury.
about
Regulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservationThe ubiquitin-proteasome system and cardiovascular diseaseTargeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategiesProtein quality control and metabolism: bidirectional control in the heartCardiac specific expression of threonine 5 to alanine mutant sarcolipin results in structural remodeling and diastolic dysfunctionProteasome inhibitors and cardiac cell growthThe ubiquitin-proteasome system in myocardial ischaemia and preconditioning.Proteasomal and lysosomal protein degradation and heart disease.Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy.Effects of a Proteasome Inhibitor on Cardiomyocytes in a Pressure-Overload Hypertrophy Rat Model: An Animal Study.Suppression of NF-κB reduces myocardial no-reflow.Cardiomyocyte p65 nuclear factor-κB is necessary for compensatory adaptation to pressure overloadNF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II.Partial inhibition of the ubiquitin-proteasome system ameliorates cardiac dysfunction following ischemia-reperfusion in the presence of high glucoseActivation of Chymotrypsin-Like Activity of the Proteasome during Ischemia Induces Myocardial Dysfunction and DeathInhibitory kappa-B kinase-β inhibition prevents adaptive left ventricular hypertrophyEnhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus.Cardiomyocyte-specific p65 NF-κB deletion protects the injured heart by preservation of calcium handling.Build it up-Tear it down: protein quality control in the cardiac sarcomere.Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease.Proteasome inhibition during myocardial infarction.Heterogeneous cardiac proteasomes: mandated by diverse substrates?Proteasome inhibitors: possible novel therapeutic strategy for ischemia-reperfusion injury?Ubiquitin and ubiquitin-like proteins in cardiac disease and protection.Relevance of mouse models of cardiac fibrosis and hypertrophy in cardiac research.Ubiquitin Ligases and Posttranslational Regulation of Energy in the Heart: The Hand that Feeds.Synergistic protection of MLC 1 against cardiac ischemia/reperfusion-induced degradation: a novel therapeutic concept for the future.Genome-Wide Expression Profiling of Anoxia/Reoxygenation in Rat Cardiomyocytes Uncovers the Role of MitoKATP in Energy Homeostasis.Role of NFkappaB in an animal model of complex regional pain syndrome-type I (CRPS-I).Clarifying the cardiac proteasome paradox: protein quality control.Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injuryBiochemical targets of drugs mitigating oxidative stress via redox-independent mechanisms.The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research.
P2860
Q27000202-2A9713FD-43FD-4028-9C8E-E716714912DFQ27021582-92ADBB20-22A2-4177-A2A1-3ADEB0047888Q27026951-7084BC12-4CD0-4A41-AB75-081CB70DA21EQ28256472-084370A2-B147-46D3-87B8-74323C5C3541Q28543394-03C4644E-05B6-4B0D-9B61-7A5A74B9840DQ33554490-F155D88C-BF7E-4629-8BFE-2644564D8C0CQ33554506-C9DA4264-8BFE-4CF3-9726-C9DEB8B0C617Q33573707-2428613F-4DCF-41AD-B65D-27E71673BF53Q33685877-8DFB781A-2343-4F71-869E-08767F91E20EQ33769449-460F87AA-6DA5-490E-85EC-D72B1139037DQ34442981-3E09A2E1-DB8E-4408-AA75-5FB7A99CF99CQ35002059-2599E1AD-F15A-4E43-82BA-9FEBD161C233Q35149277-B0CFB7E5-EF54-4525-9D90-745EB9546B3CQ35896759-2D6DBEA4-03BC-451B-84A4-F4EF7688B0BFQ36104970-1D9A3A42-4A57-41D2-A455-A895077D1C46Q36110312-1A71D09A-2607-41A1-B4E9-E9EA20A87972Q36204680-E36BC9A4-397B-45EB-81B8-97AF6B580C67Q37234808-782F4823-571F-44A8-A4C5-C3F2A7F90B0BQ37313697-906AC81D-4334-4486-AA6C-E5D678B7BC47Q37526448-5761A7A8-2239-4620-92E8-97BA0AF14D56Q37595119-B72DC96D-579A-422E-BD7B-AE4CF2E218E6Q37864471-2E8474BB-246C-460F-B4F5-F7F1322E3E7FQ38152513-733511CB-B921-46AE-8496-6CA00F76646DQ38663141-38416982-C25F-47F0-B4B1-52641B88D054Q38986995-AFD5C2A9-F919-48E4-A35D-9D598AA7865CQ39390991-81A8FDC1-6717-4818-96C1-2C9697066F28Q39451153-0E74AAB0-937C-44EF-9F6C-30EBD3D50E60Q40296185-B964C84B-540B-4702-BAAE-64CDF279D64CQ42014821-7E712E0B-403D-475D-A8D8-90897E4D065CQ42382931-E1FAE82A-0502-4CA9-9BC4-263DB0221E37Q42692416-28CDDCE9-EF6E-4AFF-88B9-873B31007278Q46269173-6A0897CB-7570-4CE5-9300-4A2622F411D5Q53495126-778FD49E-DC32-4A6E-AACD-32D5F011910E
P2860
Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Proteasome inhibition attenuat ...... l ischemia-reperfusion injury.
@en
Proteasome inhibition attenuat ...... l ischemia-reperfusion injury.
@nl
type
label
Proteasome inhibition attenuat ...... l ischemia-reperfusion injury.
@en
Proteasome inhibition attenuat ...... l ischemia-reperfusion injury.
@nl
prefLabel
Proteasome inhibition attenuat ...... l ischemia-reperfusion injury.
@en
Proteasome inhibition attenuat ...... l ischemia-reperfusion injury.
@nl
P2093
P1476
Proteasome inhibition attenuat ...... al ischemia-reperfusion injury
@en
P2093
Craig H Selzman
Nancy C Moss
Ruhang Tang
P304
P356
10.1016/J.ATHORACSUR.2007.02.049
P407
P577
2007-07-01T00:00:00Z